Literature DB >> 19770627

Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ.

Michael T Milano1, Alan W Katz, Paul Okunieff.   

Abstract

OBJECTIVES: We sought to characterize and describe the patterns of distant recurrence in patients with macroscopic oligometastases, limited in number (<or=5) and confined to one organ, treated with curative-intent stereotactic body radiotherapy (SBRT).
METHODS: Seventy-seven patients enrolled on prospective studies of SBRT for oligometastases are included in the present analysis. All available radiography and records were retrospectively reviewed to determine the timing and location of recurrences.
RESULTS: New metastases occurred in 73% of patients. Among these patients, new metastases developed most frequently in the same organ (occurring in 82% of first new metastases after SBRT and 89% of cumulative new metastases). Metastases to other organs were common as well (occurring cumulatively in 79% of patients). In patients with liver oligometastases, common sites of further progression included the liver, other abdominal organs, and lungs. In patients with lung oligometastases, common sites of further progression included the lungs, thoracic lymph nodes, bones, liver, and brain.
CONCLUSIONS: Patients receiving SBRT for oligometastases confined to one organ are apt to develop new metastases, most frequently occurring in the initially involved organ, but also commonly in other organs. A subset of patients remains disease free after extended follow-up.

Entities:  

Mesh:

Year:  2010        PMID: 19770627     DOI: 10.1097/COC.0b013e3181979238

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  23 in total

Review 1.  [Radiotherapy of hepatic metastases].

Authors:  S E Combs; K K Herfarth; D Habermehl; J Debus
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

2.  Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).

Authors:  Feras Oskan; Yvonne Dzierma; Stefan Wagenpfeil; Christian Rübe; Jochen Fleckenstein
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 3.  Radical irradiation of extracranial oligometastases.

Authors:  Joseph K Salama; Michael T Milano
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 4.  The oligometastatic state - separating truth from wishful thinking.

Authors:  David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

Review 5.  Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.

Authors:  Neil B Desai; Aaron M Laine; Robert D Timmerman
Journal:  Br J Radiol       Date:  2016-12-23       Impact factor: 3.039

6.  Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer.

Authors:  Kathrin Dellas
Journal:  Breast Care (Basel)       Date:  2011-10-13       Impact factor: 2.860

7.  Stereotactic body radiotherapy for oligo-recurrence in the liver in a patient with esophageal carcinoma: A case report.

Authors:  Atsuto Katano; Hideomi Yamashita; Keiichi Nakagawa
Journal:  Mol Clin Oncol       Date:  2017-10-04

8.  Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Authors:  Barbara Alicja Jereczek-Fossa; Sara Ronchi; Roberto Orecchia
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-07

9.  Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease.

Authors:  I S Bhattacharya; D K Woolf; R J Hughes; N Shah; M Harrison; P J Ostler; P J Hoskin
Journal:  Br J Radiol       Date:  2015-02-13       Impact factor: 3.039

Review 10.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.